Dublin, March 31, 2026 (GLOBE NEWSWIRE) — The “Brain Tumor Drugs Market Report 2026” has been added to ResearchAndMarkets.com’s offering.
The brain tumor drugs market has witnessed robust growth recently, with size projections increasing from $4.03 billion in 2025 to $4.26 billion in 2026 at a CAGR of 5.7%. This upswing is attributed to a rise in brain tumor incidence, advancements in chemotherapy drugs, enhanced symptom management awareness, hormone therapy developments, and the advent of novel anticonvulsants.
Forecasts predict the brain tumor drugs market will further escalate to $5.5 billion by 2030 at a CAGR of 6.6%. This growth is driven by the expansion of precision medicine, AI integration in drug discovery, oncology R&D advancements, increased healthcare spending, and the higher adoption of targeted therapies. Key trends are personalized chemotherapy, expanded hormone therapy applications, advanced pain management drugs, growing anticonvulsant usage for symptom control, and a broadened brain tumor drug pipeline.
Increasing chemotherapy procedures are a key growth driver, given that chemotherapy targets and destroys quickly dividing cells, including cancerous ones, thus playing a pivotal role in brain tumor treatment. For instance, over 1 million U.S. cancer patients receive chemotherapy or radiation annually, as per the Centers for Disease Control and Prevention in July 2023, amplifying the demand for brain tumor-specific drugs.
Leading companies in the market are channeling efforts towards technological innovation, exemplified by the development of targeted RAF kinase inhibitors that zero in on genetic mutations in brain tumors. These inhibitors like OJEMDA (tovorafenib) by Day One Biopharmaceuticals, introduced in November 2025, offer enhanced patient outcomes by targeting specific mutant RAF proteins with reduced systemic toxicity, marking a significant advancement in brain tumor therapies particularly for pediatric applications.
In a strategic move to enhance their neurosurgical offerings, Stryker Corporation acquired NICO Corporation in September 2024, aiming to boost minimally invasive solutions for brain tumor excision and intracerebral hemorrhage treatments. This acquisition fortifies Stryker’s neurotechnology portfolio and underscores the emphasis on innovative neurosurgical techniques.
Major industry players include F. Hoffmann-La Roche Ltd, Novartis AG, Amgen Inc., Pfizer Inc., and others. North America stood as the largest market region in 2025, while the Middle East is projected as the fastest-growing region in the coming years.
Reasons to Purchase
Delve into where the brain tumor drugs market is expanding most rapidly, its relationship to the broader economy, demographics, and analogous markets. Discover forces such as technological disruptions and regulatory shifts impacting future market trajectories. This report covers market characteristics, growth metrics, segmentation, regional dynamics, and competitive landscape, including market shares and strategies.
- Access the most extensive report on the market, covering 16 geographies, for a truly global perspective.
- Understand macro impacts on the market including geopolitical conflicts, trade policies, inflation, and regulatory landscapes.
- Leverage local data and analysis for creating targeted regional and country strategies.
- Identify lucrative growth segments for investment opportunities.
- Outperform competitors using forecast data and market drivers.
- Adapt based on end user insights and performance benchmarking against key competitors.
- Utilize the total addressable market analysis and market attractiveness scoring for strategic planning.
- Benefit from the report’s reliable data for internal and external presentations.
- Receive updated data along with an Excel dashboard for easy extraction and analysis.
Drugs Covered: Temozolomide, Bevacizumab, and other significant drugs.
End Users: Hospital and retail pharmacies, among others.
Mechanism of Action: Chemotherapy, Targeted Therapy, Hormone Therapy.
Major Companies: F. Hoffmann-La Roche Ltd, Novartis AG, Amgen Inc., Pfizer Inc., Merck & Co. Inc., and other industry leaders.
Geographical Coverage: Regions including North America, Asia-Pacific, Europe, and emerging markets like Southeast Asia and more.
Data & Delivery: Historical data plus forecasts, market sizing, and segmentation, all provided through comprehensive documents, including an interactive Excel dashboard.
Key Attributes
| Report Attribute | Details |
| No. of Pages | 250 |
| Forecast Period | 2026-2030 |
| Estimated Market Value (USD) in 2026 | $4.26 Billion |
| Forecasted Market Value (USD) by 2030 | $5.5 Billion |
| Compound Annual Growth Rate | 6.6% |
| Regions Covered | Global |
The companies featured in this Brain Tumor Drugs market report include:
- F. Hoffmann-La Roche Ltd
- Novartis AG
- Amgen Inc.
- Pfizer Inc.
- Merck & Co. Inc.
- CordenPharma
- Eisai Co. Ltd.
- Emcure Pharmaceuticals Limited
- Y-mAbs Therapeutics
- Roche India
- Novartis Oncology
- Arlak Biotech
- Healthkind Labs Pvt. Ltd.
- SwisscheM Healthcare Pvt.Ltd
- Apikos Pharma
- Kolaz Biotech
- CStone Pharma
- CARsgen Therapeutics
- JW Therapeutics
- BeiGene
- Astellas Pharma Inc
- Otsuka Pharmaceutical Co. Ltd
- Daiichi Pharmaceutical and Sankyo
- AQVIDA GmbH
- Baxter International Inc. (UK)
- AstraZeneca plc
- GlaxoSmithKline plc
- Veropharm
- Biocad
- Bristol-Myers Squibb
- Celon Pharma
- Celgene Corporation
- Johnson & Johnson
- Eli Lilly and Company
- Sandoz AG
- Eurofarma Laboratorios S.A.
- TUTEUR Argentina
- The Takeda Pharmaceutical Company Limited
- Pierre Fabre Group
- Celnova Pharma
- Pfizer S.R.L.
- Teva Pharmaceutical Industries Ltd.
- BIOPHARMA-MEA
- NeoTX
- AID Genomics Limited
- Julphar
- Sanofi
- Novo Nordisk A/S
- Bayer
- Kitov Pharma Limited
- CureTech Ltd.
- Neopharma
- Eurolab
- Aspen
- Adcock Ingram
For more information about this report visit https://www.researchandmarkets.com/r/8b504c
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
